Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 25;12(9):1378.
doi: 10.3390/jpm12091378.

Ultrathin Struts Drug-Eluting Stents: A State-of-the-Art Review

Attilio Leone  1 , Fiorenzo Simonetti  1 , Marisa Avvedimento  1 , Domenico Angellotti  1 , Maddalena Immobile Molaro  1 , Anna Franzone  1 , Giovanni Esposito  1 , Raffaele Piccolo  1
Affiliations
Review

Ultrathin Struts Drug-Eluting Stents: A State-of-the-Art Review

Attilio Leone et al. J Pers Med. .

Abstract

New-generation drug-eluting stents (DESs) represent the standard of care for patients undergoing percutaneous coronary intervention (PCI). Recent iterations in DES technology have led to the development of newer stent platforms with a further reduction in strut thickness. This new DES class, known as ultrathin struts DESs, has struts thinner than 70 µm. The evidence base for these devices consists of observational data, large-scale meta-analyses, and randomized trials with long-term follow-up, which have been conducted to investigate the difference between ultrathin struts DESs and conventional new-generation DESs in a variety of clinical settings and lesion subsets. Ultrathin struts DESs may further improve the efficacy and safety profile of PCI by reducing the risk of target-lesion and target-vessel failures in comparison to new-generation DESs. In this article, we reviewed device characteristics and clinical data of the Orsiro (Biotronik, Bülach, Switzerland), Coroflex ISAR (B. Braun Melsungen, Germany), BioMime (Meril Life Sciences Pvt. Ltd., Gujarat, India), MiStent (MiCell Technologies, USA), and Supraflex (Sahajanand Medical Technologies, Surat, India) sirolimus-eluting stents.

Keywords: coronary artery disease; drug-eluting stents; percutaneous coronary intervention; ultrathin struts.

PubMed Disclaimer

Conflict of interest statement

Giovanni Esposito reports personal fees from Abbott Vascular, Amgen, Boehringer Ingelheim, Edwards Lifesciences, Terumo, and Sanofi, outside the submitted work and research grants to the institution from Alvimedica, Boston Scientific, and Medtronic. Raffaele Piccolo reports personal fees from Abbott Vascular, Biotronik, Terumo, Amgen, Boehringer Ingelheim, and Daiichi-Sankyo, outside the submitted work. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Comparison of currently available ultrathin drug-eluting stents (DESs). CoCr: cobalt chrome; n.a.: not available, PCL: poly-caprolactone; PLGA: poly-d,l-lactide-co-glycolide; PLLA: poly-l-lactic acid; proBIO: amorphous hydrogen-rich silicon carbide; PVP: poly vinyl pyrrolidone.
See this image and copyright information in PMC

References

    1. Piccolo R., Giustino G., Mehran R., Windecker S. Stable Coronary Artery Disease: Revascularisation and Invasive Strategies. Lancet. 2015;386:702–713. doi: 10.1016/S0140-6736(15)61220-X. - DOI - PubMed
    1. Piccolo R., Pilgrim T., Heg D., Franzone A., Rat-Wirtzler J., Räber L., Silber S., Serruys P.W., Jüni P., Windecker S. Comparative Effectiveness and Safety of New-Generation Versus Early-Generation Drug-Eluting Stents According to Complexity of Coronary Artery Disease. JACC Cardiovasc. Interv. 2015;8:1657–1666. doi: 10.1016/j.jcin.2015.08.013. - DOI - PubMed
    1. Piccolo R., Franzone A., Windecker S. From Bare Metal to Barely Anything: An Update on Coronary Stenting. Heart. 2018;104:533–540. doi: 10.1136/heartjnl-2016-310877. - DOI - PubMed
    1. Tada T., Byrne R.A., Simunovic I., King L.A., Cassese S., Joner M., Fusaro M., Schneider S., Schulz S., Ibrahim T., et al. Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Second-Generation Drug-Eluting Stents. JACC Cardiovasc. Interv. 2013;6:1267–1274. doi: 10.1016/j.jcin.2013.06.015. - DOI - PubMed
    1. Chisari A., Pistritto A., Piccolo R., la Manna A., Danzi G. The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence. Int. J. Mol. Sci. 2016;17:1490. doi: 10.3390/ijms17091490. - DOI - PMC - PubMed

LinkOut - more resources